Université Paris-Sud, Centre Mère et Enfant de la Fondation Chantal Biya, Francis, POB 1936, Yaounde, Cameroon.
Centre Pasteur du Cameroun, Service d'Epidémiologie et de Santé Publique, Yaounde, Cameroon.
BMC Pediatr. 2021 Apr 21;21(1):189. doi: 10.1186/s12887-021-02664-6.
In most studies, the virological response is assessed during the first two years of antiretroviral treatment initiated in HIV-infected infants. However, early initiation of antiretroviral therapy exposes infants to very long-lasting treatment. Moreover, maintaining viral suppression in children is difficult. We aimed to assess the virologic response and mortality in HIV-infected children after five years of early initiated antiretroviral treatment (ART) and identify factors associated with virologic success in Cameroon.
In the ANRS-12140 Pediacam cohort study, 2008-2013, Cameroon, we included all the 149 children who were still alive after two years of early ART. Virologic response was assessed after 5 years of treatment. The probability of maintaining virologic success between two and five years of ART was estimated using Kaplan-Meier curve. The immune status and mortality were also studied at five years after ART initiation. Factors associated with a viral load < 400 copies/mL in children still alive at five years of ART were studied using logistic regressions.
The viral load after five years of early ART was suppressed in 66.8% (60.1-73.5) of the 144 children still alive and in care. Among the children with viral suppression after two years of ART, the probability of maintaining viral suppression after five years of ART was 64.0% (54.0-74.0). The only factor associated with viral suppression after five years of ART was achievement of confirmed virological success within the first two years of ART (OR = 2.7 (1.1-6.8); p = 0.033).
The probability of maintaining viral suppression between two and five years of early initiated ART which was quite low highlights the difficulty of parents to administer drugs daily to their children in sub-Saharan Africa. It also stressed the importance of initial viral suppression for achieving and maintaining virologic success in the long-term. Further studies should focus on identifying strategies that would enhance better retention in care and improved adherence to treatment within the first two years of ART early initiated in Sub-Saharan HIV-infected children.
在大多数研究中,在开始为 HIV 感染婴儿进行抗逆转录病毒治疗的头两年评估病毒学应答。然而,早期开始抗逆转录病毒治疗会使婴儿接受非常长期的治疗。此外,维持儿童的病毒抑制也很困难。我们旨在评估在喀麦隆开始早期抗逆转录病毒治疗(ART)后五年的 HIV 感染儿童的病毒学反应和死亡率,并确定与病毒学成功相关的因素。
在 2008 年至 2013 年期间,喀麦隆的 ANRS-12140 Pediacam 队列研究中,我们纳入了所有在开始早期 ART 两年后仍存活的 149 名儿童。在治疗 5 年后评估病毒学应答。使用 Kaplan-Meier 曲线估计在 ART 治疗 2 至 5 年内维持病毒学成功的概率。在开始 ART 五年后还研究了免疫状态和死亡率。使用逻辑回归研究了在开始 ART 五年时仍存活且仍在接受治疗的儿童中与病毒载量 <400 拷贝/ml 相关的因素。
在仍存活且接受治疗的 144 名儿童中,66.8%(60.1-73.5)在开始早期 ART 五年后病毒载量得到抑制。在开始 ART 两年后病毒抑制的儿童中,在开始 ART 五年后维持病毒抑制的概率为 64.0%(54.0-74.0)。与开始 ART 五年后病毒抑制相关的唯一因素是在前两年的 ART 中达到确认的病毒学成功(OR=2.7(1.1-6.8);p=0.033)。
在开始早期 ART 的两年至五年期间维持病毒抑制的概率相当低,这突出了在撒哈拉以南非洲,父母每天给孩子服药的困难。这也强调了初始病毒抑制对于在长期内实现和维持病毒学成功的重要性。进一步的研究应侧重于确定在撒哈拉以南地区开始早期 HIV 感染儿童开始 ART 的前两年内增强更好的护理保留率和提高治疗依从性的策略。